HC Wainwright Brokers Lower Earnings Estimates for Savara

Savara Inc. (NASDAQ:SVRA) – Investment analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Savara in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.16) per share for the quarter, down from their prior estimate of ($0.15). The consensus estimate for Savara’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for Savara’s Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.06) EPS.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02).

Several other equities analysts have also commented on the stock. Oppenheimer assumed coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective on the stock. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.14.

Savara Stock Performance

Savara stock opened at $5.27 on Friday. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -9.09 and a beta of 0.29. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a 50 day simple moving average of $5.65 and a 200-day simple moving average of $5.48. Savara has a 1-year low of $2.68 and a 1-year high of $7.01.

Institutional Trading of Savara

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Savara in the second quarter valued at about $76,966,000. Polar Capital Holdings Plc bought a new position in shares of Savara in the 4th quarter worth about $50,086,000. RTW Investments LP bought a new position in Savara in the fourth quarter worth about $35,893,000. VR Adviser LLC grew its stake in Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after buying an additional 5,626,624 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Savara in the 4th quarter worth about $27,496,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.